AIM: To investigate adherence rates in tumor necrosis factor-α (TNF-α)-inhibitors in Crohn's disease (CD) and rheumatoid arthritis (RA) by systematic review of medical literature. METHODS: A structured search of PubMed between 2001 and 2011 was conducted to identify publications that assessed treatment with TNF-α inhibitors providing data about adherence in CD and RA. Therapeutic agents of interest where adalimumab, infliximab and etanercept, since these are most commonly used for both diseases. Studies assessing only drug survival or continuation rates were excluded. Data describing adherence with TNF-α inhibitors were extracted for each selected study. Given the large variation between definitions of measurement of adherence, the definitions as used by the authors where used in our calculations. Data were tabulated and also presented descriptively. Sample size-weighted pooled proportions of patients adherent to therapy and their 95%CI were calculated. To compare adherence between infliximab, adalimumab and etanercept, the adherence rates where graphed alongside two axes. Possible determinants of adherence were extracted from the selected studies and tabulated using the presented OR. RESULTS: Three studies on CD and three on RA were identified, involving a total of 8147 patients (953 CD and 7194 RA). We identified considerable variation in the definitions and methodologies of measuring adherence between studies. The calculated overall sample size-weighted pooled proportion for adherence to TNF-α inhibitors in CD was 70% (95%CI: 67%-73%) and 59% in RA (95%CI: 58%-60%). In CD the adherence rate for infliximab (72%) was highercompared to adalimumab (55%), with a relative risk of 1.61 (95%CI: 1.27-2.03), whereas in RA adherence for adalimumab (67%) was higher compared to both infliximab (48%) and etanercept (59%), with a relative risk of 1.41 (95%CI: 1.3-1.52) and 1.13 (95%CI: 1.10-1.18) respectively. In comparative studies in RA adherence to infliximab was better than etanercept and etanercept did better than adalimumab. In three studies, the most consistent factor associated with lower adherence was female gender. Results for age, immunomodulator use and prior TNF-α inhibitors use were conflicting. CONCLUSION: One-third of both CD and RA patients treated with TNF-α inhibitors are non-adherent. Female gender was consistently identified as a negative determinant of adherence.
AIM: To investigate adherence rates in tumor necrosis factor-α (TNF-α)-inhibitors in Crohn's disease (CD) and rheumatoid arthritis (RA) by systematic review of medical literature. METHODS: A structured search of PubMed between 2001 and 2011 was conducted to identify publications that assessed treatment with TNF-α inhibitors providing data about adherence in CD and RA. Therapeutic agents of interest where adalimumab, infliximab and etanercept, since these are most commonly used for both diseases. Studies assessing only drug survival or continuation rates were excluded. Data describing adherence with TNF-α inhibitors were extracted for each selected study. Given the large variation between definitions of measurement of adherence, the definitions as used by the authors where used in our calculations. Data were tabulated and also presented descriptively. Sample size-weighted pooled proportions of patients adherent to therapy and their 95%CI were calculated. To compare adherence between infliximab, adalimumab and etanercept, the adherence rates where graphed alongside two axes. Possible determinants of adherence were extracted from the selected studies and tabulated using the presented OR. RESULTS: Three studies on CD and three on RA were identified, involving a total of 8147 patients (953 CD and 7194 RA). We identified considerable variation in the definitions and methodologies of measuring adherence between studies. The calculated overall sample size-weighted pooled proportion for adherence to TNF-α inhibitors in CD was 70% (95%CI: 67%-73%) and 59% in RA (95%CI: 58%-60%). In CD the adherence rate for infliximab (72%) was highercompared to adalimumab (55%), with a relative risk of 1.61 (95%CI: 1.27-2.03), whereas in RA adherence for adalimumab (67%) was higher compared to both infliximab (48%) and etanercept (59%), with a relative risk of 1.41 (95%CI: 1.3-1.52) and 1.13 (95%CI: 1.10-1.18) respectively. In comparative studies in RA adherence to infliximab was better than etanercept and etanercept did better than adalimumab. In three studies, the most consistent factor associated with lower adherence was female gender. Results for age, immunomodulator use and prior TNF-α inhibitors use were conflicting. CONCLUSION: One-third of both CD and RA patients treated with TNF-α inhibitors are non-adherent. Female gender was consistently identified as a negative determinant of adherence.
Authors: D E Furst; E C Keystone; J Braun; F C Breedveld; G R Burmester; F De Benedetti; T Dörner; P Emery; R Fleischmann; A Gibofsky; J R Kalden; A Kavanaugh; B Kirkham; P Mease; J Sieper; N G Singer; J S Smolen; P L C M Van Riel; M H Weisman; K Winthrop Journal: Ann Rheum Dis Date: 2012-04 Impact factor: 19.103
Authors: Jean-Frederic Colombel; Edward V Loftus; William J Tremaine; Laurence J Egan; W Scott Harmsen; Cathy D Schleck; Alan R Zinsmeister; William J Sandborn Journal: Gastroenterology Date: 2004-01 Impact factor: 22.682
Authors: Tarjei S Mikkelsen; Matthew J Wakefield; Bronwen Aken; Chris T Amemiya; Jean L Chang; Shannon Duke; Manuel Garber; Andrew J Gentles; Leo Goodstadt; Andreas Heger; Jerzy Jurka; Michael Kamal; Evan Mauceli; Stephen M J Searle; Ted Sharpe; Michelle L Baker; Mark A Batzer; Panayiotis V Benos; Katherine Belov; Michele Clamp; April Cook; James Cuff; Radhika Das; Lance Davidow; Janine E Deakin; Melissa J Fazzari; Jacob L Glass; Manfred Grabherr; John M Greally; Wanjun Gu; Timothy A Hore; Gavin A Huttley; Michael Kleber; Randy L Jirtle; Edda Koina; Jeannie T Lee; Shaun Mahony; Marco A Marra; Robert D Miller; Robert D Nicholls; Mayumi Oda; Anthony T Papenfuss; Zuly E Parra; David D Pollock; David A Ray; Jacqueline E Schein; Terence P Speed; Katherine Thompson; John L VandeBerg; Claire M Wade; Jerilyn A Walker; Paul D Waters; Caleb Webber; Jennifer R Weidman; Xiaohui Xie; Michael C Zody; Jennifer A Marshall Graves; Chris P Ponting; Matthew Breen; Paul B Samollow; Eric S Lander; Kerstin Lindblad-Toh Journal: Nature Date: 2007-05-10 Impact factor: 49.962
Authors: Kai Sun; Jackie Szymonifka; Henghe Tian; Yaju Chang; Jennifer C Leng; Lisa A Mandl Journal: Arthritis Care Res (Hoboken) Date: 2020-10 Impact factor: 4.794
Authors: Christopher Ma; Chad J Evaschesen; Grenvil Gracias; Vivian W Huang; Darryl K Fedorak; Karen I Kroeker; Levinus A Dieleman; Brendan P Halloran; Richard N Fedorak Journal: Can J Gastroenterol Hepatol Date: 2015-06-12
Authors: Danielle Bargo; Theo Tritton; Joseph C Cappelleri; Marco DiBonaventura; Timothy W Smith; Takanori Tsuchiya; Sean Gardiner; Irene Modesto; Tim Holbrook; Daniel Bluff; Taku Kobayashi Journal: Inflamm Intest Dis Date: 2021-11-17
Authors: Mike van der Have; Bas Oldenburg; Ad A Kaptein; Jeroen M Jansen; Robert C H Scheffer; Bas A van Tuyl; Andrea E van der Meulen-de Jong; Marieke Pierik; Peter D Siersema; Martijn G H van Oijen; Herma H Fidder Journal: J Crohns Colitis Date: 2016-01-06 Impact factor: 9.071
Authors: Jennifer L Barton; Laura Trupin; Dean Schillinger; Gina Evans-Young; John Imboden; Victor M Montori; Edward Yelin Journal: Arthritis Care Res (Hoboken) Date: 2016-07 Impact factor: 4.794
Authors: Mohammed A Omair; Fatima Al Suwayeh; Alanoud Almashaan; Eman Alqurtas; Mohammed K Bedaiwi; Ibrahim Almaghlouth; Abdulaziz Alkahalaf; Haya M Almalaq Journal: Patient Prefer Adherence Date: 2021-06-28 Impact factor: 2.711